G-protein-coupled receptor kinases in cardiovascular conditions: Focus on G-protein-coupled receptor kinase 2, a gain in translational medicine

Biomarkers in Medicine

Volumn 3, Issue 5, 2009, Pages 525-540

  Campanile, Alfonso ^a   Iaccarino, Guido ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

ARKct; Chronic adrenergic activation; G protein coupled receptor kinases; GPCR desensitization; GPCR downregulation; GRK2 ablation; GRK2 upregulation; Lymphocyte adrenergic signaling

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR; BETA ARRESTIN; BISOPROLOL; CARVEDILOL; CLONIDINE; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR KINASE 2; G PROTEIN COUPLED RECEPTOR KINASE 4; G PROTEIN COUPLED RECEPTOR KINASE 5; INSULIN RECEPTOR SUBSTRATE 1; METOPROLOL; MOXONIDINE; NITRIC OXIDE;

CARDIOVASCULAR DISEASE; CATECHOLAMINE SYNTHESIS; CHROMOSOME 11; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; GENE EXPRESSION PROFILING; HEART ASSIST DEVICE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; ISCHEMIC PRECONDITIONING; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; REVIEW; SYMPATHETIC INNERVATION; TISSUE DISTRIBUTION; UNSPECIFIED SIDE EFFECT; VASCULAR SMOOTH MUSCLE;

EID: 70450285420     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.09.50     Document Type: Review

References (77)

1. Pierce KL, Premont RT, Lefkowitz RJ: Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 3(9), 639-650 (2002).
2. Pitcher JA, Freedman NJ, Lefkowitz RJ: G protein-coupled receptor kinases. Annu. Rev. Biochem. 67, 653-692 (1998).
3. Premont RT, Inglese J, Lefkowitz RJ: Protein kinases that phosphorylate activated G protein-coupled receptors. FASEB J. 9(2), 175-182 (1995).
4. Willets JM, Challiss RA, Nahorski SR: Non-visual GRKs: are we seeing the whole picture? Trends Pharmacol. Sci. 24(12), 626-633 (2003).
5. Metaye T et al.: Pathophysiological roles of G-protein-coupled receptor kinases. Cell. Signal 17(8), 917-928 (2005). (Pubitemid 40719113)
6. Iaccarino G, Campanile A, Santulli G, Zuppieri F, Koch WJ: G protein-coupled receptor kinases and hypertension: a review of disease mechanisms. High Blood Press Cardiovasc. Prev. 13(4), 151-158 (2006). (Pubitemid 46115913)
7. Penela P, Ribas C, Mayor F Jr: Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases. Cell. Signal 15(11), 973-981 (2003). (Pubitemid 37130155)
8. Gros R, Benovic JL, Tan CM, Feldman RD: G-protein-coupled receptor kinase activity is increased in hypertension. J. Clin. Invest. 99(9), 2087-2093 (1997). ■ First evidence of increased G-protein-coupled receptor (GPCR) kinase (GRK)2 in peripheral blood cells and hypertension.
9. Usui I, Imamura T, Satoh H et al.: GRK2 is an endogenous protein inhibitor of the insulin signaling pathway for glucose transport stimulation. EMBO J. 23(14), 2821-2829 (2004). ■ Proposes that GRK2 also interferes with non-GPCR signaling.
10. 1- adrenergic receptors in the failing human heart. Circulation 87(2), 454-463 (1993).
11. 2-adrenergic receptor and expression of a β-adrenergic receptor kinase-1 (βARK1) inhibitor both increase myocardial contractility but have differential effects on susceptibility to ischemic injury. Circ. Res. 85(11), 1077-1084 (1999).
12. Iaccarino G, Koch WJ: Therapeutic potential of G-protein coupled receptor kinases in the heart. Expert Opin. Investig. Drugs 8(5), 545-554 (1999). (Pubitemid 29213303)
13. Penela P, Murga C, Ribas C, Tutor AS, Peregrín S, Mayor F Jr: Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease. Cardiovasc. Res. 69(1), 46-56 (2006). (Pubitemid 41814810)
14. Liggett SB, Cresci S, Kelly RJ et al.: A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure. Nat. Med. 14(5), 510-517 (2008). (Pubitemid 351655214)
15. Ribas C, Penela P, Murga C et al.: The G protein-coupled receptor kinase (GRK) interactome: role of GRKs in GPCR regulation and signaling. Biochim. Biophys. Acta 1768(4), 913-922 (2007).
16. Anis Y, Leshem O, Reuveni H et al.: Antidiabetic effect of novel modulating peptides of G-protein-coupled kinase in experimental models of diabetes. Diabetologia 47(7), 1232-1244 (2004). (Pubitemid 39093319)
17. Usui I, Imamura T, Babendure JL et al.: G protein-coupled receptor kinase 2 mediates endothelin-1-induced insulin resistance via the inhibition of both Gαq/11 and insulin receptor substrate-1 pathways in 3T3-L1 adipocytes. Mol. Endocrinol. 19(11), 2760-2768 (2005). (Pubitemid 41577248)
18. Cipolletta E, Campanile A, Santulli G et al.: The G protein coupled receptor kinase 2 plays an essential role in β-adrenergic receptor induced insulin resistance. Cardiovasc. Res. doi: 10.1093/cvr/cvp252 (2009) (Epub ahead of print).
19. Michel MC, Brodde OE, Insel PA: Peripheral adrenergic receptors in hypertension. Hypertension 16(2), 107-120 (1990).
20. 1-adrenoceptor changes in the human heart. J. Hypertens. Suppl. 4(6), S215-S218 (1986).
21. Brodde OE, Kretsch R, Ikezono K, Zerkowski HR, Reidemeister JC: Human β-adrenoceptors: relation of myocardial and lymphocyte β-adrenoceptor density. Science 231(4745), 1584-1585 (1986). (Pubitemid 16050732)
22. Iaccarino G, Barbato E, Cipolletta E et al.: Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur. Heart J. 26(17), 1752-1758 (2005). ■■ First suggestion that lymphocyte GRK2 may be used as a biomarker for heart failure.
23. 2-adrenoceptor signalling in patients with left ventricular volume overload disease. Clin. Exp. Pharmacol. Physiol. 29(3), 181-188 (2002).
24. Park SJ, Choi DJ, Kim CW: Hypertensive left ventricular hypertrophy: relation to β-adrenergic receptor kinase-1 (βARK1) in peripheral lymphocytes. J. Hypertens. 22(5), 1025-1032 (2004).
25. Hata JA, Williams ML, Schroder JN et al.: Lymphocyte levels of GRK2 (βARK1) mirror changes in the LVAD-supported failing human heart: lower GRK2 associated with improved β-adrenergic signaling after mechanical unloading. J. Card. Fail. 12(5), 360-368 (2006).
26. Cohn JN, Levine TB, Olivari MT et al.: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. 311(13), 819-823 (1984). ■■ Sets the cornerstone for neurohormonal alteration in heart failure (HF), providing evidence that increased catecholamine levels in plasma reduce prognosis.
27. Lymperopoulos A, Rengo G, Koch WJ: Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation. Trends Mol. Med. 13(12), 503-511 (2007).
28. Iaccarino G, Barbato E, Cipoletta E, Fiorillo A, Trimarco B: Role of the sympathetic nervous system in cardiac remodeling in hypertension. Clin. Exp. Hypertens. 23(1-2), 35-43 (2001).
29. Iaccarino G, Barbato E, Cipolleta E et al.: Cardiac βARK1 upregulation induced by chronic salt deprivation in rats. Hypertension 38(2), 255-260 (2001). ■ Shows that regulation of GRK2 can be induced by chronic physiological activation of the sympathetic nervous system.
30. 1-adrenergic stimulation. Hypertension 33(1 Pt 2), 396-401 (1999).
31. 1B-adrenergic receptors. J. Am. Coll. Cardiol. 38(2), 534-540 (2001). ■ Demonstrates that GRK2 increases with the development of decompensated hyperthrophy.
32. Iaccarino G, Tomhave ED, Lefkowitz RJ, Koch WJ: Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by β-adrenergic receptor stimulation and blockade. Circulation 98(17), 1783-1789 (1998). ■■ First link between chronic exposure to extracellular catecholamine and intracellular accumulation of GRK2.
33. Reiter E, Lefkowitz RJ: GRKs and β-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol. Metab. 17(4), 159-165 (2006).
34. Bristow MR, Ginsburg R, Minobe W et al.: Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N. Engl. J. Med. 307(4), 205-211 (1982).
35. Lymperopoulos A, Rengo G, Funakoshi H, Eckhart AD, Koch WJ: Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat. Med. 13(3), 315-323 (2007).
36. 2-adrenoceptors and their down-regulation in human heart failure. J. Am. Coll. Cardiol. 37(5), 1246-1251 (2001).
37. Rockman HA, Koch WJ, Lefkowitz RJ: Seven-transmembrane-spanning receptors and heart function. Nature 415(6868), 206-212 (2002).
38. Dzimiri N, Muiya P, Andres E, Al-Halees Z: Differential functional expression of human myocardial G protein receptor kinases in left ventricular cardiac diseases. Eur. J. Pharmacol. 489(3), 167-177 (2004).
39. Leineweber K, Rohe P, Beilfuss A et al.: G-protein-coupled receptor kinase activity in human heart failure: effects of β-adrenoceptor blockade. Cardiovasc. Res. 66(3), 512-519 (2005).
40. Martini JS, Raake P, Vinge LE et al.: Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc. Natl Acad. Sci. USA 105(34), 12457-12462 (2008).
41. Sorriento D, Ciccarelli M, Santulli G et al.: The G-protein-coupled receptor kinase 5 inhibits NF-κB transcriptional activity by inducing nuclear accumulation of IκBα. Proc. Natl Acad. Sci. USA 105(46), 17818-17823 (2008).
42. Koch WJ, Rockman HA, Samama P et al.: Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a βARK inhibitor. Science 268(5215), 1350-1353 (1995). ■■ First paper to place GRK2 in the cardiovascular scenario, showing that its inhibition ameliorates heart performance.
43. Rockman HA, Chien KR, Choi DJ et al.: Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc. Natl Acad. Sci. USA 95(12), 7000-7005 (1998).
44. Harding VB, Jones LR, Lefkowitz RJ, Koch WJ, Rockman HA: Cardiac βARK1 inhibition prolongs survival and augments β-blocker therapy in a mouse model of severe heart failure. Proc. Natl Acad. Sci. USA 98(10), 5809-5814 (2001). ■ Demonstrates that chronic β-blocker and inhibition of GRK2 are additive on survival in HF.
45. Tachibana H, Naga Prasad SV, Lefkowitz RJ, Koch WJ, Rockman HA: Level of β-adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure. Circulation 111(5), 591-597 (2005).
46. Swedberg K, Bristow MR, Cohn JN et al.; Moxonidine Safety and Efficacy (MOXSE) investigators: Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 105(15), 1797 - 1803 (2002).
47. Chobanian AV, Bakris GL, Black HR et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42(6), 1206-1252 (2003).
48. Harris DM, Cohn HI, Pesant S, Eckhart AD: GPCR signalling in hypertension: role of GRKs. Clin. Sci. (Lond.) 115(3), 79-89 (2008).
49. 2- adrenergic receptor gene delivery to the endothelium corrects impaired adrenergic vasorelaxation in hypertension. Circulation 106(3), 349-355 (2002).
50. Gros R, Tan CM, Chorazyczewski J, Kelvin DJ, Benovic JL, Feldman RD: G-protein-coupled receptor kinase expression in hypertension. Clin. Pharmacol. Ther. 65(5), 545-551 (1999).
51. Gros R, Chorazyczewski J, Meek MD, Benovic JL, Ferguson SS, Feldman RD: G-protein-coupled receptor kinase activity in hypertension : increased vascular and lymphocyte G-protein receptor kinase-2 protein expression. Hypertension 35(1 Pt 1), 38-42 (2000). (Pubitemid 30054234)
52. Eckhart AD, Ozaki T, Tevaearai H, Rockman HA, Koch WJ: Vascular-targeted overexpression of G protein-coupled receptor kinase-2 in transgenic mice attenuates β-adrenergic receptor signaling and increases resting blood pressure. Mol. Pharmacol. 61(4), 749-758 (2002). (Pubitemid 34273154)
53. Liu S, Premont RT, Kontos CD, Zhu S, Rockey DC: A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat. Med. 11(9), 952-958 (2005). (Pubitemid 41294440)
54. Leosco D, Iaccarino G, Cipolletta E et al.: Exercise restores β-adrenergic vasorelaxation in aged rat carotid arteries. Am. J. Physiol. Heart Circ. Physiol. 285(1), H369-H374 (2003).
55. Izzo R: Enhanced GRK2 expression and desensitization of βAR vasodilatation in hypertensive patients. Clin. Transl. Sci. 1(3) (2008).
56. 1 receptor-Gq/11α G protein-phospholipase C signaling involving G protein-coupled receptor kinase 2. Am. J. Physiol. Renal Physiol. 293(1), F306-F315 (2007).
57. Trivedi M, Lokhandwala MF: Rosiglitazone restores renal D1A receptor-Gs protein coupling by reducing receptor hyperphosphorylation in obese rats. Am. J. Physiol. Renal Physiol. 289(2), F298-F304 (2005).
58. i-mediated signaling. Circulation 112(8), 1145-1153 (2005).
59. Premont RT, Macrae AD, Stoffel RH et al.: Characterization of the G protein-coupled receptor kinase GRK4. Identification of four splice variants. J. Biol. Chem. 271(11), 6403-6410 (1996).
60. Sanada H, Jose PA, Hazen-Martin D et al.: Dopamine-1 receptor coupling defect in renal proximal tubule cells in hypertension. Hypertension 33(4), 1036-1042 (1999).
61. Choi DJ et al.: Mechanism of β-adrenergic receptor desensitization in cardiac hypertrophy is increased b-adrenergic receptor kinase. J. Biol. Chem. 272(27), 17223-17229 (1997).
62. Manning BS, Shotwell K, Mao L, Rockman HA, Koch WJ: Physiological induction of a β-adrenergic receptor kinase inhibitor transgene preserves ss-adrenergic responsiveness in pressure-overload cardiac hypertrophy. Circulation 102(22), 2751-2757 (2000).
63. Anderson KM, Eckhart AD, Willette RN, Koch WJ: The myocardial β-adrenergic system in spontaneously hypertensive heart failure (SHHF) rats. Hypertension 33(1 Pt 2), 402-407 (1999).
64. Eckhart AD, Koch WJL: Expression of a β-adrenergic receptor kinase inhibitor reverses dysfunction in failing cardiomyocytes. Mol. Ther. 5(1), 74-79 (2002).
65. Eckhart AD, Duncan SJ, Penn RB, Benovic JL, Lefkowitz RJ, Koch WJ: Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart. Circ. Res. 86(1), 43-50 (2000).
66. Matkovich SJ, Diwan A, Klanke JL et al.: Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and β-adrenergic signaling. Circ. Res. 99(9), 996-1003 (2006). (Pubitemid 44657803)
67. Fox KF, Cowie MR, Wood DA et al.: Coronary artery disease as the cause of incident heart failure in the population. Eur. Heart J. 22(3), 228-236 (2001).
68. Ungerer M, Kessebohm K, Kronsbein K, Lohse MJ, Richardt G: Activation of β-adrenergic receptor kinase during myocardial ischemia. Circ. Res. 79(3), 455-460 (1996). (Pubitemid 26276906)
69. 1 receptor mediated protection of the ischemic rat heart. J. Mol. Cell. Cardiol. 25(7), 815-821 (1993).
70. Chen EP, Bittner HB, Akhter SA, Koch WJ, Davis RD: Myocardial recovery after ischemia and reperfusion injury is significantly impaired in hearts with transgenic overexpression of β-adrenergic receptor kinase. Circulation 98(19 Suppl.), II249-II253; discussion II253-II254 (1998).
71. Yu X, Zhang M, Kyker K, Patterson E, Benovic JL, Kem DC: Ischemic inactivation of G protein-coupled receptor kinase and altered desensitization of canine cardiac β-adrenergic receptors. Circulation 102(20), 2535-2540 (2000). (Pubitemid 30839546)
72. Yu X, Huang S, Patterson E et al.: Proteasome degradation of GRK2 during ischemia and ventricular tachyarrhythmias in a canine model of myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 289(5), H1960-H1967 (2005). (Pubitemid 41507345)
73. Tong H, Rockman HA, Koch WJ, Steenbergen C, Murphy E: G protein-coupled receptor internalization signaling is required for cardioprotection in ischemic preconditioning. Circ. Res. 94(8), 1133-1141 (2004). (Pubitemid 38579709)
74. 1-adrenergic receptor polymorphisms affect functional recovery after ischemic injury. Am. J. Physiol. Heart Circ. Physiol. 290(4), H1427-H1432 (2006).
75. 2-adrenergic receptor gene on coronary artery disease. J. Am. Coll. Cardiol. 52(17), 1381-1388 (2008).
76. Raake PW, Vinge LE, Gao E et al.: G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ. Res. 103(4), 413-422 (2008).
77. Vasan RS: Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113(19), 2335-2362 (2006).